Traders should monitor the upcoming Q2 2026 clinical data readouts for MT-601 in lymphoma and the initiation of the pancreatic cancer trial, which could serve as near-term catalysts. However, declining grant revenue and persistent losses raise funding risk beyond 2026 without dilution or new grants.
MRKR drugs
MRKR drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Mar 19 $1.32entry
- T+1 · 8mo ago +1.52%α +3.26% · $1.34
- T+5 · 8mo ago +2.27%α +4.48% · $1.35
- T+20 · 7mo ago +25.76%α +18.14% · $1.66
- T+60 · 5mo ago +4.55%α −9.80% · $1.38
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Marker Therapeutics reported financial results for 2025, highlighting a net loss increase to $12.2 million despite lower R&D spending, while maintaining a $17 million cash position expected to fund operations into Q4 2026. The company emphasized strong clinical progress, including a 66% objective response rate in lymphoma and promising pancreatic cancer data, with key updates expected in Q2 2026.
Key Financial Metrics
Key Facts
- Net loss widened to $12.2 million in 2025 from $10.7 million in 2024 despite lower R&D expenses ($11.8M vs $13.5M).
- Cash, cash equivalents, and restricted cash totaled $17.0 million at year-end 2025, down from $19.2 million in 2024.
- Cash runway expected through Q4 2026 without additional grant funding.
- MT-601 showed 66% objective response rate (8/12 patients) in relapsed non-Hodgkin lymphoma with 50% complete responses.
- Nature Medicine publication reported up to 84.6% disease control rate in pancreatic cancer with MT-601 combination therapy.
- Company-sponsored pancreatic cancer trial expected to initiate in Q2 2026.
- Grant income declined sharply to $3.5M in 2025 from $6.6M in 2024.
Financial Impact
Revenue declined 46% YoY to $3.5M due to lower grant income; net loss increased 13% despite cost reductions; cash burn was $12.0M in 2025.
Risk Factors
- Limited cash runway extending only to Q4 2026 with no guarantee of additional grant disbursements.
- Heavy reliance on non-dilutive funding; decline in grant income raises sustainability concerns.
- Clinical-stage biotech risk: value hinges on unproven therapies with no near-term revenue potential.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3258655 |
Track record
5 reports on MRKR
The track record builds as more bullish or bearish reports settle.
Filters
- Oct 19, 202628d ago 8-K Bullish 5/10 Entry $1.20 to $0.8700 Now $0.8300 −30.83% ▼ −27.50% −24.04% vs SPY
- Oct 19, 202628d ago Press Release Bullish 5/10 Entry $1.20 to $0.8286 Now $0.8300 −30.83% ▼ −30.95% −27.49% vs SPY
- Mar 20, 202634w ago DEFA14A Neutral 4/10 Entry $1.31 to $1.56 Now $0.8300 −36.64% ▲ +19.08% +11.66% vs SPY
- Mar 19, 202634w ago 8-K Mixed 6/10 Entry $1.32 to $1.66 Now $0.8300 −37.12% ▲ +25.76% +18.14% vs SPY
- Mar 18, 202634w ago Press Release Mixed 6/10 Viewing Entry $1.32 to $1.66 Now $0.8300 −37.12% ▲ +25.76% +18.14% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers